The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon. The three-year study found that a daily drop in each eye of a low dose of atropine, a drug used to dilate pupils, was better than a placebo at limiting eyeglass prescription changes and inhibiting elongation of the eye in nearsighted children aged 6 to 10.